# A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

> **NCT05780736** · — · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 33 (actual)

## Conditions studied

- Esophageal Carcinoma
- Gastroesophageal Junction Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05780736
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-04
- **Primary completion:** 2024-08-23
- **Final completion:** 2024-08-23
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** A decision was made to terminate the study due to expected timelines associated with start-up, participant enrollment, ethics committee approval and data availability from the study.
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780736, "A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05780736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*